Recurrent and Metastatic Head and Neck Cancer: A Paradigm Shift?
Head and neck squamous cell carcinoma (HNSCC), the most prevalent pathological subtype of head and neck carcinoma (HNC), can be potentially cured if diagnosed at early stages and adequately treated. Still, most patients are diagnosed at stages III or IV disease, with estimated local and distant fail...
Main Authors: | Leonor Abreu Ribeiro, Cecília Melo Alvim, Helena Luna Pais, Luis Marques Costa |
---|---|
Format: | Article |
Language: | English |
Published: |
José de Mello Saúde
2020-09-01
|
Series: | Gazeta Médica |
Subjects: | |
Online Access: | https://www.gazetamedica.pt/index.php/gazeta/article/view/337 |
Similar Items
-
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
by: Hyera Kim, et al.
Published: (2020-08-01) -
Evolving role of immunotherapy in head-and-neck cancers: A systemic review
by: Raajit Chanana, et al.
Published: (2018-01-01) -
Immunotherapy and its advances in the management of head-and-neck cancer
by: Sajad Ahmad Buch, et al.
Published: (2019-01-01) -
Carboplatin-pemetrexed in treatment of patients with recurrent/metastatic cancers of the head and neck; superior outcomes in oropharyngeal primaries.
by: Binu eMalhotra, et al.
Published: (2015-01-01) -
Nestin Expression Is Associated with Relapses in Head and Neck Lesions
by: Mario Pérez-Sayáns, et al.
Published: (2021-03-01)